Anti-amyloid therapy for Alzheimer’s disease has received renewed encouragement with the recent FDA approval of the second-generation monoclonal antibody lecanemab and the pending approval of donanemab. Read More
Neurofilament-light chain (NfL) and glial fibrillary acidic protein (GFAP) are two of the main fluid biomarkers currently being examined for their clinical utility in evaluating disease activity, progression and treatment response. However, there are a number of other biomarkers under investigation. The following is a summary of some of the more promising candidates (reviewed in Maroto-Garcia et al. Clin Chim Acta 2023;548:117471). Read More
The prospective REDUCE-GAD study reports that higher serum neurofilament-light chain (NfL) levels are associated with the presence of contrast-enhancing (CE) lesions, which may enable clinicians to forego contrast agents for follow-up MRIs (Schaefer et al. Eur J Neurol 2023;30:2393-2400). Read More
Ken, a 53-year-old man, was initially seen in 2017 following onset of painful spasms in R leg and probable clonus while driving his car. He developed R leg weakness and band-like discomfort across his chest. He was worked up for stroke and cardiac issues and all investigations were negative. He had a prior history of asthma with nasal polyps and NSAID-associated dyspnea.